Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126884481 | 12688448 | 1 | I | 20160523 | 20160826 | 20160826 | PER | US-ASTRAZENECA-2016SE55942 | ASTRAZENECA | 0.00 | M | Y | 98.90000 | KG | 20160826 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126884481 | 12688448 | 1 | SS | ATENOLOL. | ATENOLOL | 1 | Oral | 0 | 25 | MG | TID | ||||||||
| 126884481 | 12688448 | 2 | PS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 160/4.5 MCG ONE PUFF TWICE A DAY | 21929 | ||||||||||
| 126884481 | 12688448 | 3 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 126884481 | 12688448 | 4 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 0 | 500 | MG | BID | |||||||||
| 126884481 | 12688448 | 5 | C | NAPROXIN | NAPROXEN | 1 | 0 | 500 | MG | BID | |||||||||
| 126884481 | 12688448 | 6 | C | WARFARIN | WARFARIN | 1 | 0 | 1 | MG | ||||||||||
| 126884481 | 12688448 | 7 | C | GABAPENTIN. | GABAPENTIN | 1 | 0 | 400 | MG | ||||||||||
| 126884481 | 12688448 | 8 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | 0 | 1 | MG | BID | |||||||||
| 126884481 | 12688448 | 9 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | 40 | MG | BID | |||||||||
| 126884481 | 12688448 | 10 | C | KLOR-CON | POTASSIUM CHLORIDE | 1 | 0 | 20 | MG | QD | |||||||||
| 126884481 | 12688448 | 11 | C | DIAZEPAM. | DIAZEPAM | 1 | 0 | 5 | MG | TID | |||||||||
| 126884481 | 12688448 | 12 | C | ASPRIN | ASPIRIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126884481 | 12688448 | 1 | Blood pressure abnormal |
| 126884481 | 12688448 | 2 | Chronic obstructive pulmonary disease |
| 126884481 | 12688448 | 4 | Diabetes mellitus |
| 126884481 | 12688448 | 5 | Pain |
| 126884481 | 12688448 | 6 | Atrial fibrillation |
| 126884481 | 12688448 | 9 | Fluid retention |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126884481 | 12688448 | Atrial fibrillation | |
| 126884481 | 12688448 | Cardiac disorder | |
| 126884481 | 12688448 | Chronic obstructive pulmonary disease | |
| 126884481 | 12688448 | Diabetes mellitus | |
| 126884481 | 12688448 | Diabetic neuropathy | |
| 126884481 | 12688448 | Hypertension | |
| 126884481 | 12688448 | Intentional product misuse | |
| 126884481 | 12688448 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126884481 | 12688448 | 2 | 201602 | 0 |